Understanding OUR Cytokine-Based Immunotherapy Candidates Our dedication extends to advancing a robust portfolio of programs aimed toward growing the horizons of cytokine-based immunotherapy, specifically for cancers where cure solutions remain limited. Utilize the links below to learn additional about our portfolio of cytokine-based immunotherapy candidates. Take a look at https://financefeeds.com/cme-group-and-dtcc-to-expand-cross-margining/